Efficacy of Electroencephalography (EEG) Neurofeedback (NF) for the Treatment of Anxiety Disorder

• Status: Recruiting
• Trial end date: 2023-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to assess the efficacy of electroencephalography (EEG) neurofeedback (NF) as an Add-on Treatment for the Anxiety disorder. Meanwhile, evaluate the effect of EEG-NF on cognitive function of Anxiety patients. Furthermore, the investigators will examine the changes in cortisol, gut microbiome and some biomarkers. The hypothesis of this study is that EEG-NF alleviate the anxiety symptoms and improve the cognitive function of Anxiety disorder patients with regulating attention response.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Tianjin Anding Hospital
• Treatments: Antidepressive Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Hypnotics and Sedatives

Criteria

Inclusion Criteria:

• a current episode of Anxiety diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)

• age between 18 and 50 years

• a total score of HAMD ≥14 GAD-7≥ 5

• Participants are compliant with treatment according to the judgement of the treating clinician.

• Participant or guardian has to sign informed consent. The patients' guardians will sign the informed consent on behalf of the participants when the capacity of participants to consent is compromised.

Exclusion Criteria:

• History of alcohol or drug abuse;

• Severe somatic diseases including conditions such as kidney and liver failure, uncontrolled hypertension, cardiovascular, cerebrovascular and pulmonary disease, thyroid disease, diabetes, epilepsy and asthma.

• Use of anti-inflammatory medication for longer than 7 days in the last two months preceding the trial

• Use of immunosuppressive medication such as oral steroid hormones Women in pregnancy or lactation period